Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience

Annals of Thoracic Surgery

Volumn 89, Issue 2, 2010, Pages 570-576

  Karsies, Todd J ^a   Nicol, Kathleen K ^a,b   Galantowicz, Mark E ^a,b   Stephens, Julie A ^c   Kerlin, Bryce A ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; CARDIOPULMONARY ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HEART SURGERY; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; TRANSFUSION;

ADOLESCENT; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; FEMALE; HEART DEFECTS, CONGENITAL; HEMOSTASIS, SURGICAL; HUMANS; INFANT; LENGTH OF STAY; MALE; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; REOPERATION; RETROSPECTIVE STUDIES; THROMBOSIS;

EID: 74549175676     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.11.023     Document Type: Article

References (27)

1. Razon Y., Erez E., Vidne B., Katz J., Tamari H., and Dagan O. Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 15 (2005) 235-240
2. Szekely A., Cserep Z., Sapi E., et al. Risks and predictors of blood transfusion in pediatric patients undergoing open heart operation. Ann Thorac Surg 87 (2009) 187-197
3. The Society of Thoracic Surgeons Blood Conservation Guidelines Task Force. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 83(5 suppl):S27-86.
4. Triulzi D. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg 108 (2009) 770-776
5. Odegard K., McGowan F., Zurakowski D., et al. Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann Thorac Surg 73 (2002) 1770-1777
6. Kaulitz R., Ziemer G., Rauch R., et al. Prophylaxis of thromboembolic complications after the Fontan operation (total cavopulmonary anastamosis). J Thorac Cardiovasc Surg 129 (2005) 569-575
7. Binotto M., Maeda N., and Lopes A. Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation. Cardiol Young 15 (2005) 26-30
8. Procelewska M., Kolcz J., Januszewska K., Mroczek T., and Malec E. Coagulation abnormalities and liver function after hemi-Fontan and Fontan procedures-the importance of hemodynamics in the early postoperative period. Eur J Cardiothorac Surg 31 (2007) 866-872
9. Odegard K., Zurakowski D., Hornykewycz S., et al. Evaluation of the coagulation system in children with two-ventricle congenital heart disease. Ann Thorac Surg 83 (2007) 1797-1804
10. Martinowitz U., and Michaelson M. on behalf of the Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 3 (2005) 640-648
11. Karkouti K., Beattie W.S., Wijeysundera D.N., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45 (2005) 26-34
12. Egan J., Lammi A., Schell D., Gillis J., and Nunn G. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 30 (2004) 682-685
13. Tobias J., Sinsic J., Weinstein S., Schechter W., Kartha V., and Michler R. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med 19 (2004) 270-273
14. Franchinia M., Manzatob F., Salvagnoc G.L., and Lippic G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis 18 (2007) 589-593
15. Sachs B., Delacy D., Green J., et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. Spine 32 (2007) 2285-2293
16. Mayer S., Brun N., Begrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
17. Pugliese F., Ruberto F., Summonti D., et al. Activated recombinant factor VII in orthotopic liver transplantation. Transplant Proc 39 (2007) 1883-1885
18. Rizoli S., Boffard K., Riou B., et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 10 (2006) R178
19. Agarwal H., Bennett J., Churchwell K., et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 84 (2007) 161-169
20. Ekert H., Brizard C., Eyers R., Cochrane A., and Henning R. Elective administration in infants of low dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 17 (2006) 389-395
21. Jenkins K., Gauvreau K., Newburger J., Spray T., Moller J., and Iezzoni L. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg 123 (2002) 110-118
22. Al-Radi O., Harrell F., Calderone C., et al. Case complexity scores in congenital heart surgery: a comparative study of the Aristotle basic complexity score and the risk adjustment in congenital heart surgery (RACHS-1) system. J Thorac Cardiovasc Surg 133 (2007) 865-874
23. Mullen P., Wessel D., Thomas K., et al. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg 107 (2008) 371-378
24. Schmugge M., Risch L., Huber A., Benn A., and Fischer J. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 109 (2002) e10
25. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artific Organs 23 (1999) 979-983
26. Riccabona M., Kuttnig-Haim M., Dacar D., et al. Venous thrombosis in and after extracorporeal membrane oxygenation: detection and follow-up by color Doppler sonography. Eur Radiol 7 (1997) 1383-1386
27. Spinella P., Perkins J., McLaughlin D., et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 64 (2008) 286-294